Olema Pharmaceuticals Inc Market Cap ($642.00 Million)
Market Cap & Net Worth: Olema Pharmaceuticals Inc (OLMA)
Olema Pharmaceuticals Inc market cap. Olema Pharmaceuticals Inc (NASDAQ:OLMA) has a market capitalization of $642.00 Million ($642.00 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10629 globally and #2841 in its home market, demonstrating a 11.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Olema Pharmaceuticals Inc's stock price $7.35 by its total outstanding shares 87347471 (87.35 Million). Also see OLMA cash flow metrics for how efficiently the company converts equity into cash flow.
Olema Pharmaceuticals Inc Market Cap History (2020–2026)
Olema Pharmaceuticals Inc market cap history from 2020 to 2026. Data shows change from $4.20 Billion to $642.00 Million (-27.27% CAGR). Check latest Olema Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Index Memberships
Olema Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.02% | #295 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1107 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.04% | #174 of 263 |
Weight: Olema Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Olema Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Olema Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore OLMA net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OLMA by Market Capitalization
Companies near Olema Pharmaceuticals Inc in the global market cap rankings as of November 4, 2026. Also see Olema Pharmaceuticals Inc (OLMA) total assets for a full breakdown of the balance sheet.
Key companies related to Olema Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Olema Pharmaceuticals Inc (2020–2026)
Market capitalization of Olema Pharmaceuticals Inc from 2020 to today. Between 2020 and today, Olema Pharmaceuticals Inc's market cap moved from $4.20 Billion to $ 642.00 Million, with a yearly change of -27.27%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $642.00 Million | -70.60% |
| 2025 | $2.18 Billion | +328.82% |
| 2024 | $509.24 Million | -58.45% |
| 2023 | $1.23 Billion | +472.65% |
| 2022 | $214.00 Million | -73.82% |
| 2021 | $817.57 Million | -80.53% |
| 2020 | $4.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Olema Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $642.00 Million USD |
| MoneyControl | $642.00 Million USD |
| MarketWatch | $642.00 Million USD |
| marketcap.company | $642.00 Million USD |
| Reuters | $642.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive,… Read more